Rachel C. Jankowitz, MD
Adjuvant endocrine therapy has become the standard treatment for patients with hormone receptor (HR)–positive, HER2-negative breast cancer. However, while therapeutic developments and longer follow-up data have led to a shift to more individualized treatment, a lack of consensus persists.
State of the Science Summit™ on Breast Cancer, Jankowitz, assistant professor of medicine at the University of Pittsburgh School of Medicine and the University of Pittsburgh Medical Center Hillman Cancer Center, discussed the range of risk associated with HR-positive, HER2-negative breast cancer, important factors physicians should consider when choosing the appropriate therapy, and the importance of communicating with patients about associated adverse events (AEs).
OncLive: Could you provide an overview of your presentation on adjuvant hormonal therapy in earlystage breast cancer?
The beginning part of my presentation was an overview of duration of tamoxifen therapy and how we arrived at 10 years of tamoxifen being superior to 5 years in this patient population.
The other important thing that we need to consider when talking to our patients about these therapies is tolerance, quality of life, and AEs. Often, more aggressive hormonal therapies are accompanied by AEs. We’re always weighing these incremental gains against how well patients are tolerating these therapies and how high breast cancer risk was to begin with.
Could you explain how 10 years of tamoxifen use proved to be superior to 5 years? What else do we know now about aromatase inhibitors?
The ATLAS and aTTom trials are 2 very large studies that looked at approximately 17,000 women with early-stage breast cancer who were randomized to receive either 10 years or 5 years of tamoxifen. It took a long time to see this, but at about 10 years of follow-up you started to see an improvement in disease-free survival [DFS] with 10 years of tamoxifen use compared with 5 years.
... to read the full story